O. Reg. 645/05: GENERAL

 

ontario regulation 645/05

made under the

Ontario drug benefit act

Made: December 7, 2005
Filed: December 9, 2005
Published on e-Laws: December 12, 2005
Printed in The Ontario Gazette: December 24, 2005

Amending O. Reg. 201/96

(General)

1. (1) The definition of “Formulary” in subsection 1 (1) of Ontario Regulation 201/96 is revoked and the following substituted:

“Formulary” means the Ministry of Health and Long-Term Care publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 39) dated September 27, 2005, and includes the following amendments to the publication,

1. Amendments dated January 12, 2006;

(2) Section 1 of the Regulation is amended by adding the following subsection:

(1.1) For the purposes of this Regulation, items 17 and 18 of Part III of the Formulary shall be read as follows:

VORICONAZOLE

17	50mg Tab			11.8800
	02256460	Vfend	PFI	11.8800
18	200mg Tab			47.5000
	02256479	Vfend	PFI	47.5000
	Reason for Use Code	Clinical Criteria
	399	Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole. The first prescription must be written by a physician based at the hospital where the patient was hospitalized. Note: Limited to 3 months of reimbursement.  LU Authorization Period: 1 year.

2. Clause 12 (1) (b) of the Regulation is amended by striking out “Canadian Coordinating Office of Health Technology Assessment” wherever it appears and substituting in each case “Canadian Coordinating Office for Health Technology Assessment.”

3. This Regulation comes into force on January 12, 2006.